Asahi Kasei Bioprocess America (AKBA) is devoted to solving therapeutic product safety, efficiency and purity challenges within the pharmaceutical and bioprocessing industries. With technology platforms for virus filtration, chromatography, inline buffer formulation and oligonucleotide synthesis, our bioprocessing systems, columns and automation solutions advance GMP manufacturing of critical drug substances around the world. By focusing our expertise on fluid management technology, our portfolio of market-driven equipment and cutting-edge technology touches unit operations across a wide range of therapeutic modalities, including classical small molecule pharmaceuticals, current-generation antibodies, plasma derivatives and next-generation oligonucleotide therapeutics.
Asahi Kasei Bioprocess is committed to providing high quality and innovative equipment and filtration solutions by delivering what customers need, continuously improving processes and living by our values every day.
In this podcast, we spoke with Nainesh Shah, Senior Application Engineer at Asahi Kasei Bioprocess about buffer management including the benefits of inline buffer formulation, and single use inline buffer formulation systems. Buffer Management We started ... Continued
Enhance Downstream Bioprocessing Efficiency with AKBA’s Award-Winning MOTIV™ Inline Buffer Formulation (IBF™) Systems
Buffer formulation is an essential part of downstream bioprocessing to produce safe and effective biopharmaceuticals more efficiently. Buffers are aqueous solutions with precise pH and ionic strength that can stabilize proteins, aid purification steps, as ... Continued
Simplified, Closed Slurry Preparation to Manage a Wide Range of Chromatography Media for DAC LC Columns
Slurry preparation is a critical step in preparing a well-packed column and achieving a successful bioprocess purification. However, this step can be challenging as different therapeutics require different chromatography media to achieve effective chromatographic separation. ... Continued
The oligonucleotide industry is experiencing a surge of interest and momentum thanks to the discovery of the CRISPR-Cas9 system and the development of RNA-based vaccines and therapies. Oligonucleotides represent one of the most promising therapeutic ... Continued
In this podcast, we interviewed Katie Keller, Director of Quality and Safety at Asahi Kasei Bioprocess America, about the importance of quality management and how to achieve the best possible results. Topics included the most ... Continued
Cory Hinz talks about the different methods that are available for liquid chromatography mobile phase solutions and the benefits of inline blending. Cory also describes how to implement binary blending feeding of a liquid chromatography process using inline blending....Continued
Ergonomic design enables routine column maintenance by one operator in as little as 15 minutes Chromatography columns are an integral part of many biologic purification processes. As such there has been an increase in the use ... Continued
The biopharma industry has continued to embrace automation as a key part of creating more efficient, cost-effective manufacturing. There are many options for how to automate systems, but a universal requirement is the need for ... Continued
The regulatory approval of several oligonucleotides over the past five years – combined with the recent headlines around rapid COVID-19 vaccine development – has created significant interest in the oligonucleotide (DNA/RNA) segment of the scientific ... Continued
With over 300 candidates in clinical trials, oligonucleotides are one of the most promising therapeutic modalities and for the foreseeable future – and solid phase synthesis remains the gold standard approach for manufacturing. Benefits include ... Continued
In this podcast, we spoke with Chris Rombach, Vice President of Sales and Marketing at Asahi Kasei Bioprocess America about buffer prep and delivery systems. We discussed current pain points and how next generation buffer prep solutions can greatly improve upon the status quo, including increasing the use of automation and remote operation, while reducing the overall footprint, labor and cost associated with more traditional approaches. ...Continued